DORCHESTER WEALTH MANAGEMENT Co boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% during the second quarter, Holdings Channel reports. The institutional investor owned 68,610 shares of the biopharmaceutical company’s stock after buying an additional 196 shares during the period. Gilead Sciences accounts for about 1.7% of DORCHESTER WEALTH MANAGEMENT Co’s holdings, making the stock its 21st largest position. DORCHESTER WEALTH MANAGEMENT Co’s holdings in Gilead Sciences were worth $4,856,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the company. Hall Laurie J Trustee raised its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares in the last quarter. Cable Hill Partners LLC increased its stake in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. increased its stake in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the last quarter. Finally, Penserra Capital Management LLC increased its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the last quarter. Hedge funds and other institutional investors own 74.06% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down 0.41% on Friday, hitting $72.40. 7,029,745 shares of the stock traded hands. The firm has a market capitalization of $94.55 billion, a PE ratio of 7.86 and a beta of 1.21. The firm’s 50 day moving average is $72.36 and its 200 day moving average is $68.77. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $82.10.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same period last year, the company earned $3.08 earnings per share. The firm’s revenue was down 8.2% compared to the same quarter last year. On average, analysts expect that Gilead Sciences, Inc. will post $8.76 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/08/12/gilead-sciences-inc-nasdaqgild-stake-raised-by-dorchester-wealth-management-co.html.

GILD has been the subject of several research analyst reports. Cowen and Company reissued a “buy” rating and issued a $100.00 target price on shares of Gilead Sciences in a research report on Monday, April 17th. Stifel Nicolaus reissued a “buy” rating and issued a $87.00 target price on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 target price for the company in a research report on Tuesday, May 2nd. Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.88 target price for the company. in a research report on Tuesday, April 25th. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, April 21st. Twelve investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences presently has a consensus rating of “Buy” and a consensus price target of $80.31.

In other news, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $74.00, for a total value of $2,960,000.00. Following the sale, the executive vice president now directly owns 137,488 shares in the company, valued at $10,174,112. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares in the company, valued at $227,197,799. The disclosure for this sale can be found here. Insiders sold 206,666 shares of company stock worth $15,223,184 over the last quarter. 1.30% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.